

Appln. No. 10/524,787  
Amd. dated September 7, 2010  
Reply to Office Action of May 4, 2010

**Amendments to the Claims**

This listing of claims will replace all prior versions,  
and listings of claims in the application:

**Listing of Claims:**

1(Currently Amended). An isolated tumor associated antigen (TAA) peptide of eight to ten amino acid residues, which is capable of promoting effective binding to a MHC class I molecule to elicit a CTL response and which is encoded by a polynucleotide overexpressed in human colon carcinoma cells, ~~which polynucleotide is selected from the group consisting of human defensin 6 gene, human ADP/ATP translocase gene, human parathymosin gene, human 1-8U interferon inducible gene, human chaperonin-like protein gene, human SPARC/osteonectin gene, human 1-8D interferon inducible gene, human TB2 gene, human alpha-1 collagen gene, human mRNA for dipeptidase, fibronectin gene, actin binding protein gene, HCG IV mRNA, HLA-DR antigens associated invariant gamma chain gene, MHC class I HLA-C.1 gene, polyA binding protein gene, transforming growth factor beta induced gene, human mRNA for laminin binding protein, human mRNA sequence gene, insulin like growth factor II gene, human ribosomal protein L23a mRNA, human acidic ribosomal phosphoprotein P1 gene, human liver mRNA fragment DNA binding protein UPI gene, ribosomal protein L37 gene, human MHC protein~~

Appln. No. 10/524,787  
Amd. dated September 7, 2010  
Reply to Office Action of May 4, 2010

~~homologous to chicken B complex gene and HB23 gene for B23~~  
~~nucleophosmin,~~ selected from the group consisting of the amino  
acid sequence of SEQ ID NO:27, SEQ ID NO:11; SEQ ID NO:25, SEQ ID  
NO:16, SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:22,

wherein said peptide optionally includes one  
conservative amino acid substitution.

Claims 2-6 (Cancelled).

7(Currently amended). The peptide of claim 14 which  
has the amino acid sequence of SEQ ID NO:27.

Claims 8-12 (Cancelled).

13(Currently Amended). The peptide of claim 1, which  
includes one conservative amino acid substitution.

Claim 14 (Cancelled).

15(Previously presented). A composition, comprising a  
pharmaceutically acceptable carrier, excipient, diluent or  
auxiliary agent and at least one peptide of claim 1.

16(Previously presented). The composition of claim 15,  
further comprising a helper peptide.

17(Previously presented). The composition of claim 16,  
wherein said helper peptide contains a T helper epitope.

Claims 18-20 (Cancelled).

21(Previously presented). The composition of claim 15  
which is a cell composition, wherein the pharmaceutically

acceptable carrier is an antigen presenting cell which presents said at least one peptide.

22(Previously presented). The composition of claim 21, wherein said antigen presenting cell is selected from the group consisting of a dendritic cell, a macrophage, a B cell, and a fibroblast.

23(Previously presented). The composition of claim 22, wherein said antigen presenting cell is caused to present said at least one tumor associated antigen peptide by a method selected from the group consisting of:

- (A) genetically modifying said antigen presenting cell with at least one polynucleotide encoding said at least one tumor associated antigen peptide such that said peptide or at least one polypeptide which comprises said peptide is expressed;
- (B) loading said antigen presenting cell with at least one polynucleotide encoding said at least one tumor associated antigen peptide;
- (C) loading said antigen presenting cell with said at least one tumor associated antigen peptide; and
- (D) loading said antigen presenting cell with at least one polypeptide comprising said at least one tumor associated antigen peptide.

Appln. No. 10/524,787  
Amd. dated September 7, 2010  
Reply to Office Action of May 4, 2010

Claims 24-58 (Cancelled).

59(Previously presented). An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:61.

Claims 60-61 (Cancelled).

62(Currently amended). The peptide of claim 1, which does not include one conservative amino acid substitution.

63(Currently amended). The peptide of claim 14 which has the amino acid sequence of SEQ ID NO:11.

64(Currently amended). The peptide of claim 14 which has the amino acid sequence of SEQ ID NO:25.

65(Previously presented). The peptide of claim 1, which has the amino acid sequence of SEQ ID NO:16.

66(Previously presented). The peptide of claim 1, which has the amino acid sequence of SEQ ID NO:20.

67(Previously presented). The peptide of claim 1, which has the amino acid sequence of SEQ ID NO:21.

68(Previously presented). The peptide of claim 1, which has the amino acid sequence of SEQ ID NO:22.